BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31804164)

  • 1. Proteomics of Pancreatic Neuroendocrine Tumors: A Systematic Review.
    Maiorano BA; Schinzari G; Chiloiro S; Visconti F; Milardi D; Bianchi A
    Protein Pept Lett; 2020; 27(12):1276-1287. PubMed ID: 31804164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
    Park JK; Paik WH; Lee K; Ryu JK; Lee SH; Kim YT
    Oncotarget; 2017 Jul; 8(30):49796-49806. PubMed ID: 28591701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinical analysis on functioning pancreatic neuroendocrine tumors (focusing on VIPomas): a single-center experience.
    Murakami M; Fujimori N; Matsumoto K; Ohno A; Teramatsu K; Takamatsu Y; Takeno A; Ueda K; Oono T; Ito T; Ogawa Y
    Endocr J; 2022 Oct; 69(10):1201-1209. PubMed ID: 35644576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre- and intraoperative diagnostic requirements, benefits and risks of minimally invasive and robotic surgery for neuroendocrine tumors of the pancreas.
    Gharios J; Hain E; Dohan A; Prat F; Terris B; Bertherat J; Coriat R; Dousset B; Gaujoux S
    Best Pract Res Clin Endocrinol Metab; 2019 Oct; 33(5):101294. PubMed ID: 31351817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Neuroendocrine Tumors: A Systematic Review and Metanalysis.
    Armellini E; Facciorusso A; Crinò SF
    Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837560
    [No Abstract]   [Full Text] [Related]  

  • 6. A review of functional pancreatic neuroendocrine tumors: Exploring the molecular pathogenesis, diagnosis and treatment.
    Alshareefy Y; Cummins S; Mazzoleni A; Sharma V; Guggilapu S; Leong AWY; Wireko AA
    Medicine (Baltimore); 2023 Nov; 102(46):e36094. PubMed ID: 37986400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers.
    Havasi A; Sur D; Cainap SS; Lungulescu CV; Gavrilas LI; Cainap C; Vlad C; Balacescu O
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-genome sequencing reveals distinct genetic bases for insulinomas and non-functional pancreatic neuroendocrine tumours: leading to a new classification system.
    Hong X; Qiao S; Li F; Wang W; Jiang R; Wu H; Chen H; Liu L; Peng J; Wang J; Jia C; Liang X; Dai H; Jiang J; Zhang T; Liao Q; Dai M; Cong L; Han X; Guo D; Liang Z; Li D; Zheng Z; Ye C; Li S; Zhao Y; Wu K; Wu W
    Gut; 2020 May; 69(5):877-887. PubMed ID: 31462556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACTH-secreting pancreatic neoplasms associated with Cushing syndrome: clinicopathologic study of 11 cases and review of the literature.
    Maragliano R; Vanoli A; Albarello L; Milione M; Basturk O; Klimstra DS; Wachtel A; Uccella S; Vicari E; Milesi M; Davì MV; Scarpa A; Sessa F; Capella C; La Rosa S
    Am J Surg Pathol; 2015 Mar; 39(3):374-82. PubMed ID: 25353285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative Lengthening of Telomeres and Differential Expression of Endocrine Transcription Factors Distinguish Metastatic and Non-metastatic Insulinomas.
    Hackeng WM; Schelhaas W; Morsink FHM; Heidsma CM; van Eeden S; Valk GD; Vriens MR; Heaphy CM; Nieveen van Dijkum EJM; Offerhaus GJA; Dreijerink KMA; Brosens LAA
    Endocr Pathol; 2020 Jun; 31(2):108-118. PubMed ID: 32103422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.
    Zhang P; Li YL; Qiu XD; Luo J; Shi YF; Sun YL; Su F; Qi ZR; Tan HY
    World J Surg Oncol; 2019 Apr; 17(1):66. PubMed ID: 30975157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic relevance of UCH-L1 and α-internexin in pancreatic neuroendocrine tumors.
    Song YL; Yu R; Qiao XW; Bai CM; Lu CM; Xiao Y; Zhong DR; Chen J; Zhao YP; Zhang TP; Song TT; Gao HL; Wan YH; Shen L; Chen J; Lv B; Hao JJ; Zhang Y; Tang L; Chen YJ
    Sci Rep; 2017 May; 7(1):2205. PubMed ID: 28526880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of cell-of-origin epigenetic characteristics in non-functional pancreatic neuroendocrine tumors.
    Dreijerink KM; Hackeng WM; Singhi AD; Heaphy CM; Brosens LA
    J Pathol; 2022 Feb; 256(2):143-148. PubMed ID: 34750813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are Cystic Pancreatic Neuroendocrine Tumors an Indolent Entity Results from a Single-Center Surgical Series.
    Paiella S; Marchegiani G; Miotto M; Malpaga A; Impellizzeri H; Montagnini G; Pollini T; Nessi C; Butturini G; Capelli P; Posenato I; Scarpa A; D'Onofrio M; De Robertis R; Cingarlini S; Boninsegna L; Bassi C; Salvia R; Landoni L
    Neuroendocrinology; 2018; 106(3):234-241. PubMed ID: 28586782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systems biology approach to define mechanisms, phenotypes, and drivers in PanNETs with a personalized perspective.
    Werle SD; Ikonomi N; Lausser L; Kestler AMTU; Weidner FM; Schwab JD; Maier J; Buchholz M; Gress TM; Kestler AMR; Kestler HA
    NPJ Syst Biol Appl; 2023 Jun; 9(1):22. PubMed ID: 37270586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy.
    de Wilde RF; Edil BH; Hruban RH; Maitra A
    Nat Rev Gastroenterol Hepatol; 2012 Feb; 9(4):199-208. PubMed ID: 22310917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic relevance of aberrant DNA methylation in g1 and g2 pancreatic neuroendocrine tumors.
    Stefanoli M; La Rosa S; Sahnane N; Romualdi C; Pastorino R; Marando A; Capella C; Sessa F; Furlan D
    Neuroendocrinology; 2014; 100(1):26-34. PubMed ID: 25011998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancements in pancreatic neuroendocrine tumors.
    Sadaria MR; Hruban RH; Edil BH
    Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5):477-90. PubMed ID: 23899286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of clinicopathological features, hormone immunoexpression, and loss of ATRX and DAXX expression in pancreatic neuroendocrine tumors.
    Yadav R; Kakkar A; Sharma A; Malik PS; Sharma MC
    Scand J Gastroenterol; 2016 Aug; 51(8):994-9. PubMed ID: 27162024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of p27
    Conemans EB; Raicu-Ionita GM; Pieterman CRC; Dreijerink KMA; Dekkers OM; Hermus AR; de Herder WW; Drent ML; van der Horst-Schrivers ANA; Havekes B; Bisschop PH; Offerhaus GJ; Borel Rinkes IHM; Valk GD; Timmers HTM; Vriens MR
    J Endocrinol Invest; 2018 Jun; 41(6):655-661. PubMed ID: 29134609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.